Tilavonemab in Early Alzheimer's Disease: Results from a Phase 2, Randomized, Double-Blind Study.
Hana Florian,Deli Wang,Steven E. Arnold,Merce Boada,Qi Guo,Ziyi Jin,Hui Zheng,Nahome Fisseha,Hari Varun Kalluri,Beatrice Rendenbach-Mueller,Kumar Budur,Michael Gold, Thomas Aware Investigators,Lealani Acosta,Thomas Ala, Sanka Amadoru, Jeffrey Apter,Steven Arnold,Merce Boada-Rovira, Anne Boerjesson-Hanson, Wendy Bond,Michael Borrie,Gabriella Bottini, Bruce Brew,Mark Brody,James Burke,Jeffrey Burns,Annalisa Chiari,Roger Clarnette,Sharon Cohen,Martin Farlow, Simon Fishman,Norman Foster,Kristian Frederiksen,Giovanni Frisoni, Nigel Gilchrist,Darren Gitelman,Ira Goodman,Marc Gordon,Neill Graff-Radford,Merja Hallikainen,Adrian Ivanoiu,Gregory Jicha,Michael Jonsson,Diana Kerwin,Dineke Koek,James Lah, Ayesha Lall, Elly Lee,Gabriel Leger,Peter Ljubenkov,Camillo Marra,Pablo Martinez-Lage,Joseph Masdeu,Scott McGinnis,Patrizia Mecocci,Philip Morris, Marshall Nash,Allison Perrin,Aimee Pierce,Robert Riesenberg,Juha Rinne, Raquel Sanchez Del Valle,Elio Scarpini,Paul Schulz,Ronald Schwartz,Amanda Smith,Bryan Spann, Sylvie Van Snick,Rik Vandenberghe, Cherian Verghese,Alberto Villarejo,Chuang-Kuo Wu Brain（2023）
Key words
Alzheimer's disease,amyloid positron emission tomography,anti-tau antibodies,tau positron emission tomography,volumetric magnetic resonance imaging
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper